Biotech Values

[donotknowityet]

Dew,

I think you refer to the Eximias deal.
Which was again last Spring.
For the purpoee of explaining their personal and business spending after the financing which was done previously is irrelevant.

My point was again is that last Fall the CEO made a sizeable open market purchase. Same time the company spent heavily on understanding how Tesm attacks multi -drug resistant/cancer stem cells, and they claimed to be in the process of filing patents about them.

Can you explain the reason for that?
The money raised previously does not explain that.
And they were not in the process of raising money during the time between these and the announcement of outcome.